The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence

British Journal of General Practice

Volumn 55, Issue 511, 2005, Pages 139-146

  Simoens, Steven ^a   Matheson, Catriona ^b   Bond, Christine ^b   Inkster, Karen ^b   Ludbrook, Anne ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Buprenorphine; Methadone; Opiate dependence; Primary health care; Systematic review

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE;

ADULT; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MEDICAL LITERATURE; MEDICAL RESEARCH; OPIATE ADDICTION; POPULATION DISTRIBUTION; POPULATION RESEARCH; PRESCRIPTION; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; BUPRENORPHINE; COMMUNITY HEALTH SERVICES; HUMANS; METHADONE; MIDDLE AGED; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS;

EID: 13844277079     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Davoli M, Perucci CA, Rapiti E, et al. A persistent rise in mortality among injection drug users in Rome, 1980 through 1992. Am J Public Health 1997; 87: 851-853.
2. Hagan H, Thiede H, Weiss NS, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-46.
3. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001; 61: 195-206.
4. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Cochrane Review). In: Cochrane Collaboration. The Cochrane Library Issue 4. Oxford: Update Software, 2003.
5. Cochrane Collaboration. Cochrane reviewers' handbook 4.1.4. Updated October 2001. http://www.cochrane.org/resources/handbook/index.htm (accessed 22 December 2004.)
6. West SL, O'Neal KK, Graham CW. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 2000; 12: 405-414.
7. Abbott PJ, Weller SB, Delaney HD, Moore BA. Community reinforcement approach in the treatment of opiate addicts. Am J Drug Alcohol Abuse 1998; 24: 17-30.
8. Chutuape MA, Silverman K, Stitzer ML. Use of methadone take-home contingencies with persistent opiate and cocaine abusers. J Subst Abuse Treat 1999; 16: 23-30.
9. Curran HV, Bolton J, Wanigaratne S, Smyth C. Additional methadone increases craving for heroin: a double blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. Addiction 1999; 94: 665-674.
10. Fiellin DA, O'Connor PG, Chawarski M, et al. Methadone maintenance in primary care. A randomised controlled trial. JAMA 2001; 286: 1724-1731.
11. Kidorf M, Stitzer ML, Brooner RK, Goldberg J. Contingent methadone take-home doses reinforce adjunct therapy attendance of methadone maintenance patients. Drug Alcohol Depend 1994; 36: 221-226.
12. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269: 1953-1959.
13. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry 2000; 57: 395-404.
14. Preston KL, Umbricht A, Epstein DH. Abstinence reinforcement maintenance contingency and one-year follow up. Drug Alcohol Depend 2002; 67: 125-137.
15. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence. JAMA 2000; 283: 1303-1310.
16. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119: 23-27.
17. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomised trial. JAMA 1999; 281: 1000-1005.
18. Woody GE, McLellan AT, Luborsky L, O'Brien CP. Psychotherapy in community methadone programs: a validation study. Am J Psychiatry 1995; 152: 1302-1308.
19. Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomised trial of an interim methadone maintenance clinic. Am J Public Health 1991; 81: 1185-1191.
20. Ahmadi J. Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran. J Subst Abuse Treat 2002; 22: 157-159.
21. Ahmadi J. A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. Drug Alcohol Depend 2002; 66: 111-114.
22. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994; 54: 1215-1228.
23. Amass L, Bickel WK, Crean JP, et al. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology 1998; 136: 217-225.
24. Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology 1999; 146: 111-118.
25. Perez de los Cobos JP, Martin S, Etcheberrigaray A, et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend 2000; 59: 223-233.
26. Eissenberg T, Bigelow GE, Strain EC, et al. Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomised clinical trial. JAMA 1997; 277: 1945-1951.
27. Greenwald MK, Johanson CE, Schuster CR. Opioid reinforcement in heroin dependent volunteers during outpatient buprenorphine maintenance. Drug Alcohol Depend 1999; 56: 191-203.
28. Greenwald MK, Schuh KJ, Hopper JA, et al. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behaviour by humans. Psychopharmacology 2002; 160: 344-352.
29. Gross A, Jacobs EA, Petry NM, Badger GJ, Bickel WK. Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days. Drug Alcohol Depend 2001; 64: 111-116.
30. Johnson RE, Eissenberg T, Stitzer ML, et al. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40: 17-25.
31. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomised clinical trial. Addiction 1998; 93: 475-486.
32. O'Connor PG, Oliveto AH, Shi JM, et al. A randomised trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998; 105: 100-105.
33. Petry NM, Bickel WK, Badger GJ. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin Pharmacol Ther 1999; 66: 306-314.
34. Petry NM, Bickel WK, Badger GJ. A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible? Addiction 2000; 95: 1069-1077.
35. Petry NM, Bickel WK, Badger GJ. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addiction 2001; 96: 823-834.
36. Resnick RB, Galanter M, Pycha C, et al. Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull 1992; 28: 109-113.
37. Schottenfeld RS, Pakes JR, O'Connor P, et al. Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry 2000; 47: 1072-1079.
38. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat 2003; 24: 217-220.
39. Eder H, Fischer G, Gombas W, et al. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 1998; 4: 3-7.
40. Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94: 1337-1347.
41. Johnson RE, Fudala PJ, Jaffe JH. Outpatient comparison of buprenorphine and methadone maintenance. I. Effects on opiate use and self-reported adverse effects and withdrawal symptomatology. NIDA Res Monogr 1991; 105: 585-586.
42. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267: 2750-2755.
43. Johnson R, Chutuape M, Strain E, et al. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-1297.
44. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181: 358-364.
45. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53: 401-407.
46. Mattick RP, Ali R, White JM, et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98: 441-452.
47. Pani PP, Maremmani I, Pirastu R, et al. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60: 39-50.
48. Petitjean S, Stohler R, Deglon JJ, et al. Double-blind randomised trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62: 97-104.
49. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54: 713-720.
50. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151: 1025-1030.
51. Uehlinger C, Deglon JJ, Livoti S, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Eur Addict Res 1998; 4: 13-18.
52. Information and Statistics Division. Drug Misuse Statistics, 2001. Edinburgh: Scottish Executive, 2002.
53. Krantz MJ, Mehler PS. Treating opioid dependence. Growing implications for primary care. Arch Intern Med 2004; 164(3 : 277-288.
54. Department of Health, Scottish Home and Health Department Welsh Office. Drug misuse and dependence: guidelines on clinical management. London: The Stationery Office, 1999.
55. Royal College of General Practitioners. Royal College of General Practitioners Guidance for the use of buprenorphine for the treatment of opioid dependence in primary care. London: Royal College of General Practitioners, 2004.
56. Matheson C, Pitcairn J, Bond CM, et al. General practice management of illicit drug users in Scotland: a national survey. Addiction 2003; 98: 119-126.